Can MRI-Guided radiation offer a safer way to treat kidney cancer?
NCT ID NCT07767500
First seen Aug 17, 2026 · Last updated Aug 17, 2026
Summary
This trial is testing whether MRI-guided radiation therapy can treat early-stage kidney cancer with fewer side effects than standard CT-based radiation. The study enrolls adults with kidney cancer who are not candidates for surgery or who decline it. Participants receive a single, high-dose radiation treatment guided by real-time MRI, which allows precise targeting and motion tracking. The goal is to see if this approach reduces treatment-related complications while effectively controlling the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MRI-guided radiation therapy (MRgRT) using the Elekta Unity MR linac system, delivering stereotactic body radiotherapy (SBRT) at 26 Gy in one fraction.
- What this could lead to
- If successful, this approach could offer a safer, non-surgical treatment option for early-stage kidney cancer patients who cannot or choose not to have surgery, with fewer side effects.
- What could go wrong
- This is a small, early-phase study (30 participants) without a comparison group, so results may not be definitive. Radiation to the kidney carries risks, including potential damage to surrounding organs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY STAGE RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NYU Langone Health
New York, New York, 10016, United States